BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: Targeting BRAF-V600E mutations with a combination of Dabrafenib and Trametinib has shown promising results and was approved by the Food and Drug Administration (FDA) as a first-line therapy for advanced or metastatic anaplastic thyroid cancer (Subbiah et al. 2018; Zhao et al. 2023).